STOCK TITAN

Aptevo Therapeutics (APVO) director converts 400 RSUs into 400 common shares

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aptevo Therapeutics Inc. director Grant Grady III exercised 400 Restricted Stock Units (RSUs) into 400 shares of common stock on August 6, 2026. The RSUs convert into common stock on a one-for-one basis. Following the transaction, Grady directly holds 1,150 shares of Aptevo common stock, while the corresponding RSU position was reduced to zero.

Positive

  • None.

Negative

  • None.
Insider Grant Grady III
Role Director
Type Security Shares Price Value
Exercise Restricted Stock Unit F1, F2 400 $0.00 $0.00
Exercise Common Stock F1 400 -- --
Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct); Common Stock — 1,150 shares (Direct)
Footnotes (2)
  1. F1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
  2. F2. On August 6, 2025, the reporting person was granted 7,200 (400 post-split) RSUs, vesting on the first anniversary of the date of grant.
RSUs Exercised 400 RSUs Restricted Stock Units converted into common stock on August 6, 2026
Common Shares Received 400 shares Shares of Aptevo common stock received upon RSU conversion
Shares Held After Transaction 1,150 shares Direct common stock holdings of Grant Grady III after the exercise
Par Value $0.001 per share Par value of Aptevo common stock into which RSUs convert
Original RSU Grant 7,200 RSUs (400 post-split) Grant to Grant Grady III on August 6, 2025, vesting after one year
Restricted Stock Unit financial
"Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
derivative security financial
"transaction_action is described as a derivative exercise/conversion of a derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
par value financial
"common stock, $0.001 par value per share, of the Issuer"
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
vest financial
"RSUs, vesting on the first anniversary of the date of grant"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Aptevo Therapeutics (APVO) director Grant Grady III report in this Form 4?

Grant Grady III reported exercising 400 RSUs into 400 shares of Aptevo common stock on August 6, 2026. This was recorded as an exercise or conversion of a derivative security into common stock.

How many Aptevo Therapeutics (APVO) shares does Grant Grady III own after this transaction?

After the transaction, Grant Grady III directly owns 1,150 shares of Aptevo common stock. The derivative RSU position tied to this exercise is shown as 0 units remaining in the filing data.

What type of securities did the RSUs convert into for Aptevo Therapeutics (APVO)?

The RSUs converted into common stock of Aptevo Therapeutics, with a stated $0.001 par value per share. The conversion occurred on a one-for-one basis between each RSU and one share of common stock.

How many Restricted Stock Units did Grant Grady III exercise in Aptevo Therapeutics (APVO)?

Grant Grady III exercised 400 Restricted Stock Units, which converted into 400 shares of common stock. The Form 4 identifies this as an exercise or conversion of a derivative security with no remaining units from this block.

When were the Aptevo Therapeutics (APVO) RSUs originally granted to Grant Grady III?

The RSUs were originally granted on August 6, 2025, in an amount of 7,200 RSUs (400 post-split). According to the footnote, they were scheduled to vest on the first anniversary of the grant date.

Were any Aptevo Therapeutics (APVO) shares sold in this Form 4 transaction?

No sales are reported. The filing shows an exercise of 400 RSUs into common stock and a resulting 1,150 shares held directly, with no separate sale transaction listed in the data.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Grant Grady III

(Last)(First)(Middle)
2401 4TH AVENUE
SUITE 1050

(Street)
SEATTLE WASHINGTON 98121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/06/2026M400A(1)1,150D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(1)08/06/2026M400 (2) (2)Common Stock400$00D
Explanation of Responses:
1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
2. On August 6, 2025, the reporting person was granted 7,200 (400 post-split) RSUs, vesting on the first anniversary of the date of grant.
/s/ SoYoung Kwon, Attorney-in-Fact08/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)